pipobroman - Profile

What are the generic sources for pipobroman and what is the scope of freedom to operate?

Pipobroman is the generic ingredient in one branded drug marketed by Abbott and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for pipobroman

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for pipobroman

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbott	VERCYTE	pipobroman	TABLET;ORAL	016245-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Abbott	VERCYTE	pipobroman	TABLET;ORAL	016245-002	Approved Prior to Jan 1, 1982		DISCN	No	No

Investment Scenario and Fundamentals Analysis for Pipobroman

Last updated: February 20, 2026

What is Pipobroman?

Pipobroman is an alkylating agent used primarily for treating certain blood disorders. It belongs to the class of ether compounds with immunosuppressive and chemotherapeutic properties. Its primary application historically includes the treatment of polycythemia vera, a myeloproliferative neoplasm. Pipobroman is not approved in the United States but is used in some European countries, especially France.

Market Overview and Regulatory Status

Aspect	Details
Approved Regions	France, some other European countries
Regulatory status	Not approved by FDA or EMA; off-label and compassionate use
Patent status	Original patent expired; no recent patent filings reported
Market size	Limited, primarily niche; global estimates approximate €10-20 million per year

Clinical and R&D Fundamentals

• Efficacy: Demonstrates effectiveness in controlling hematologic parameters in polycythemia vera, but limited data on long-term outcomes.
• Safety: Risks include secondary malignancies, marrow suppression, and hepatotoxicity.
• Development pipeline: No recent clinical trials registered; limited ongoing R&D activity.
• Competing therapies: Hydroxyurea dominates first-line treatment; interferons and JAK inhibitors (e.g., ruxolitinib) are emerging.

Investment Considerations

Market Potential

• Few existing drugs target polycythemia vera with acceptable safety profiles.
• Market is constrained by regional approval restrictions; mainly limited to France and select European countries.
• No recent regulatory submissions or approvals indicate declining interest or clinical obsolescence.

R&D and Commercialization Challenges

• Lack of patent protection reduces incentives for investment.
• The safety profile concerns hinder development of new formulations.
• Off-label use limits revenue impact for manufacturers.

Competitive Landscape

Competitors	Market Position	Key Drugs
Hydroxyurea	Standard first-line therapy	Hydroxyurea
Ruxolitinib (JAK inhibitor)	Approved for myelofibrosis and polycythemia vera	Ruxolitinib
Interferons	Alternative, limited by tolerability	Interferon-alpha

Investment Risks & Opportunities

Risks	Impact
Limited geographic approval	Restricts market size
Safety concerns and side effects	Limits patient acceptance
Lack of patent protection	Diminishes commercial exclusivity
Competition from newer, targeted therapies	Reduces market share

Opportunities	Rationale
Niche market for specific patient groups	Rare indications can justify higher treatment costs
Potential for reformulation or combination use	Can improve safety or efficacy
Biomarker-driven therapy development	Patients with specific molecular profiles

Financial Outlook

• Revenue growth prospects are minimal, barring regulatory approval expansion.
• R&D investments are unlikely to yield high returns currently.
• Merging with or licensing from companies holding other polycythemia vera treatments could be an option but remains unlikely based on current activity.

Regulatory Environment and Policy

• The drug faces a challenging regulatory environment outside France.
• EU and US agencies prioritize safety and new mechanism therapies, not older chemotherapeutic agents.
• Limited incentives exist to promote development or reapproval of pipobroman.

Key Takeaways

• Pipobroman has limited commercial potential due to regional approval restrictions, safety concerns, and competition.
• The market is largely confined to niche indications, with slow or stagnant growth.
• No active clinical development or patent protections diminish its attractiveness for investment.
• Clinical benefits are recognized but overshadowed by safety risks and newer therapies.
• Strategic opportunities are primarily limited to niche, orphan, or off-label markets rather than large-scale commercialization.

Frequently Asked Questions

1. Is pipobroman approved outside Europe? Yes, in some European countries like France, but not in the US, Canada, or Australia.

2. What are the main safety risks associated with pipobroman? The drug has risks of secondary malignancies, marrow suppression, and hepatotoxicity.

3. Are there ongoing clinical trials for pipobroman? No significant registered trials or R&D activities are underway currently.

4. Can pipobroman be repurposed or reformulated? Limited potential exists due to safety concerns and lack of patent protection.

5. What are the competitive advantages of pipobroman? Its niche status may afford some utility in specific patient populations; however, the overall outlook is limited.

References

1. [1] European Medicines Agency. (2021). Summary of Product Characteristics: Pipobroman.
2. [2] ClinicalTrials.gov. (2023). Clinical trials involving pipobroman.
3. [3] European Patent Office. (2020). Patent status for alkylating agents.
4. [4] National Institutes of Health. (2022). Overview of treatments for polycythemia vera.
5. [5] U.S. Food and Drug Administration. (2022). Drug approval status.